Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02617589
Title Study of Nivolumab Versus Temozolomide, Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (CheckMate 498)
Acronym CheckMate 498
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications
Therapies
Age Groups: adult
Covered Countries USA | SWE | POL | NOR | NLD | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CHE | CAN | BEL | AUT | AUS


No variant requirements are available.